|
Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Business Market Research
Energy Market Research
Financial Market Research
Pharmaceutical Market Research
Telecoms Market Research
|
Home > Market Research > Prescription Medicines > Global Pharmaceutical Markets
This Report:
The global market for pharmaceuticals increased from $693.7 billion in 2007 to an estimated $737.6 billion by the end of 2008. It should reach over $1 trillion by 2013, a compound annual growth rate (CAGR) of 6.9%.
The generic prescription drugs segment will experience the highest growth rate over the study period. Worth an estimated $88.7 billion in 2008, it will reach $151.4 billion by the end of 2013, a CAGR of 11.3%.
The world’s best selling pharmaceutical product, Lipitor, had revenues of $12.7 billion in 2007.
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This study examines world pharmaceutical markets and provides pertinent information about sales and production of pharmaceutical products, as well as information about national healthcare systems and drug pricing policies. The report covers 24 countries in detail and provides links to relevant information. There are also profiles of larger pharmaceutical and biotechnology companies, complete with revenue histories.
Trends in government policies concerning drug pricing and reimbursement are examined. The report also makes predictions about countries whose pharmaceutical market growth is likely to grow radically in the next 5 years.
REASONS FOR DOING THE STUDY
Although the pharmaceutical industry remains one of the most profitable and stable industries in the world, several variables are forcing fundamental changes in its structure. They are:
Increasing government-imposed price reductions in prices
An increasing role of generic substitutes (especially in Europe)
The emergence of bio-pharmaceuticals and the bio-omics revolution
Increasing buyer power of third-party payers, government buyers, and health maintenance organizations
Increased health awareness among patients and government buyers
Changing suppliers?enhanced outsourcing, in-licensing, contract research, and manufacturing activities.
Additionally, changing world demographics are influencing the pharmaceutical industry. They include population aging, declining research and development (R&D) productivity, and the General Agreements on Tariffs and Trade (GATT) and Trade Related Intellectual Property Rights (TRIPS).
AUDIENCE FOR THE REPORT
This report is directed at decision-makers in each industry segment, as well as at individuals and organizations considering investing in drug discovery or drug discovery technology. These people include, but are not limited to the following:
Business development professionals
Venture capitalists
Merger and acquisition executives
Market and product management professionals
Chief scientists and technical officers
Equipment manufacturers
Reagent suppliers
SCOPE AND FORMAT
The scope of this study encompasses the major sectors of the world pharmaceutical industry and major geographical markets. BCC Research has analyzed the forces affecting the world pharmaceutical markets, determined their impact on the market demand and growth, and also presented the growth forecast over the next 5 years. Key forces include the increasing role of substitutes (generic pharmaceuticals), threat of new entrants (biopharmaceuticals), increasing role of buyers (governments, insurance, etc.), and changing suppliers.
BCC Research has provided the comprehensive analyses of the industry on the worldwide basis and also provided the detailed profiles for 25 leading pharmaceutical markets across the globe. For each of the geographical markets, we have presented the sector information, pharmaceutical distribution and pricing, and reimbursement and regulations. In a nutshell, the report provides the reader with a one-stop analysis of the worldwide pharmaceutical industry.
METHODOLOGY AND INFORMATION SOURCES
Market data and other information used in this report was gathered from interviews with individuals in the industry, as well as a thorough review of technology and markets gathered from secondary sources. These sources include company annual, 10K and 10Q reports, company literature, trade literature, trade associations, and online sources. Note that the author of this report is herself involved in the development of a compound for amyotrophic lateral sclerosis.
Projections were based on current and historical levels of funding and revenues, potential end users, likely unit prices and rates of consumption. Final projections are based on the analysis of information from primary and secondary sources. All currency conversions were made based on the average value of the dollar during the last month of the year in question. In some cases, data is provided in the original currency for readers wishing to make their own comparisons. An online currency converter was used for this purpose.[1] All forecasts are presented in year 2008 constant dollars.
TABLE 192 GENERIC PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ BILLIONS)
Over-the-Counter Medications
TABLE 193 OTC PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ MILLIONS)
IMPORTANT ORGANIZATIONS IN FINLAND
STATISTICS FINLAND
IMPORTANT ORGANIZATIONS IN EUROPE
THE EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS (EFPIA)
THE EUROPEAN GENERICS ASSOCIATION (EGA)
THE ASSOCIATION OF THE EUROPEAN SELFMEDICATION INDUSTRY (AESGP)
ASIA
JAPAN
INTRODUCTION
TABLE 194 OVERALL PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 195 POPULATION TRENDS, JAPAN, THROUGH 2013 (MILLIONS)
TABLE 196 DEMOGRAPHIC TRENDS, JAPAN, THROUGH 2013 (MILLIONS)
FIGURE 32 JAPAN: POPULATION, 1998-2013 (MILLIONS)
THE JAPANESE HEALTHCARE SYSTEM
Healthcare Expenditures in Japan
TABLE 197 HEALTHCARE EXPENDITURE: JAPAN, 2000-2005
Common Health Problems in Japan
TABLE 198 LEADING CAUSES OF DEATH, JAPAN, 2005
Cancer
TABLE 199 LEADING FORMS OF CANCER, JAPAN, 2005
Alzheimer’s Disease and Related Dementias
Obesity and Diabetes
Cardiovascular Disease
Smoking
PHARMACEUTICAL PRICING
Pharmaceutical Pricing (Continued)
Pricing of Generic Drugs
MARKET SECTORS
Branded Prescription Pharmaceuticals
TABLE 120 BRANDED PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)
Generic Drugs
TABLE 201 GENERIC PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)
OVER-THE-COUNTER MEDICATIONS IN JAPAN
TABLE 202 OTC PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)
TABLE 203 LEADING OTC CATEGORIES, JAPAN
IMPORTANT ORGANIZATIONS IN JAPAN
STATISTICS BUREAU
MINISTRY OF HEALTH, LABOUR, & WELFARE
JPMA, JAPAN PHARMACEUTICAL MANUFACTURER’S ASSOCIATION
JSMI, JAPANESE SELF-MEDICATION INDUSTRY
COMPANY PROFILES
ASTELLAS PHARMA
SAWAI PHARMACEUTICAL COMPANY LTD
TAKEDA PHARMACEUTICAL COMPANY LTD.
CHINA
INTRODUCTION
TABLE 204 OVERALL PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 205 POPULATION TRENDS, CHINA, THROUGH 2013 (MILLIONS)
TABLE 206 DEMOGRAPHIC TRENDS, CHINA, THROUGH 2013 (MILLIONS)
HEALTHCARE AND HEALTH PROBLEMS IN CHINA
The Healthcare System
Pharmaceutical Pricing
Health Problems in China
MARKET SECTORS
Branded Prescription Pharmaceuticals
TABLE 207 PRESCRIPTION PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 ($ BILLIONS)
Generic Drugs
Over-the-Counter Medications
TABLE 208 OTC PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 ($ MILLIONS)
IMPORTANT ORGANIZATIONS IN CHINA
NATIONAL BUREAU OF STATISTICS OF CHINA
SOUTH KOREA
INTRODUCTION
TABLE 209 OVERALL PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 210 POPULATION TRENDS, SOUTH KOREA, THROUGH 2013 (MILLIONS)
TABLE 211 DEMOGRAPHIC TRENDS, SOUTH KOREA, THROUGH 2013 (MILLIONS)
HEALTHCARE AND HEALTH PROBLEMS IN SOUTH KOREA
The Healthcare System
Pharmaceutical Pricing
Health Problems in South Korea
TABLE 212 LEADING CAUSES OF DEATH, SOUTH KOREA, 2003
MARKET SECTORS
Branded and Generic Prescription Pharmaceuticals
TABLE 213 PRESCRIPTION PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 ($ BILLIONS)
Over-the-Counter Medications
TABLE 214 OTC PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 ($ MILLIONS)
IMPORTANT ORGANIZATIONS IN SOUTH KOREA
KOREAN NATIONAL STATISTICAL OFFICE
AUSTRALIA
INTRODUCTION
TABLE 215 OVERALL PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 216 POPULATION TRENDS, AUSTRALIA, THROUGH 2013 (MILLIONS)
HEALTHCARE AND HEALTH PROBLEMS IN AUSTRALIA
The Healthcare System (Medicare)
Pharmaceutical Pricing
Health Problems in Australia
TABLE 217 LEADING CAUSES OF DEATH, MEN, AUSTRALIA, 2005 (% OF ALL DEATHS)
TABLE 218 LEADING CAUSES OF DEATH, WOMEN, AUSTRALIA, 2004 (% OF ALL DEATHS)
TABLE 219 COMMON CHRONIC CONDITIONS, AUSTRALIA, 2005 (% OF POPULATION)
MARKET SECTORS
Branded Prescription Pharmaceuticals
TABLE 220 BRANDED PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ BILLIONS)
Generic Drugs
TABLE 221 GENERIC PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ BILLIONS)
Over-the-Counter Medications
TABLE 222 OTC PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ MILLIONS)
TABLE 223 TOP OTC PURCHASES, AUSTRALIA (% OF THE POPULATION)
IMPORTANT ORGANIZATIONS IN AUSTRALIA
AUSTRALIAN BUREAU OF STATISTICS
DEPARTMENT OF INNOVATION, INDUSTRY, SCIENCE, AND RESEARCH
MEDICINES AUSTRALIA
INDIA
INTRODUCTION
TABLE 224 OVERALL PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 225 POPULATION TRENDS, INDIA, THROUGH 2013 (MILLIONS)
HEALTHCARE AND HEALTH PROBLEMS IN INDIA
Pharmaceutical Pricing
HEALTH PROBLEMS IN INDIA
MARKET SECTORS
Overview
TABLE 226 TOP INDIAN PHARMACEUTICAL COMPANIES BY REVENUES, 2006 ($ MILLIONS)
Barriers to Growth in India
Branded Prescription Pharmaceuticals
TABLE 227 PRESCRIPTION PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 ($ BILLIONS)
Generics
Over-the-Counter Medications
TABLE 228 OTC PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 ($ BILLIONS)
IMPORTANT ORGANIZATIONS IN INDIA
MINISTRY OF STATISTICS AND PROGRAMME IMPLEMENTATION
MINISTRY OF HEALTH
IDMA, THE INDIAN DRUG MANUFACTURERS ASSOCIATION
OPPI, THE ORGANISATION OF PHARMACEUTICAL PRODUCERS OF INDIA
COMPANY PROFILES
RANBAXY LABORATORIES, LTD
CIPLA LTD
DR. REDDY’S LABORATORIES LTD.
SOME INTERESTING LINKS RELATED TO HEALTH, PHARMACEUTICALS, AND DISEASE
PHARMACEUTICAL MARKETS IN SELECTED COUNTRIES NOT COVERED IN DETAIL IN THIS REPORT
PHARMACEUTICAL MARKETS IN SELECTED COUNTRIES ?
PHARMACEUTICAL MARKETS?(CONTINUED)
SOME INTERESTING LINKS RELATED TO HEALTH, PHARMACEUTICALS, AND DISEASE
LIST OF TABLES
SUMMARY TABLE WORLDWIDE MARKET PHARMACEUTICAL
PRODUCTS, THROUGH 2013 ($ BILLIONS)
TABLE 1 HEALTHCARE EXPENDITURES, COUNTRIES IN THIS
REPORT, 2000 AND 2005 (% OF GDP)
TABLE 2 WORLDWIDE LEADING ETHICAL PHARMACEUTICAL
COMPANIES: SALES AND MARKET SHARE, 2006 AND 2007
($ BILLIONS)
TABLE 3 WORLDWIDE LEADING PHARMACEUTICAL COMPANIES BY
R&D SPENDING, 2006 AND 2007 ($ BILLIONS)
TABLE 4 LARGEST PHARMACEUTICAL MARKETS (OVERALL), 2006
AND 2007 ($ BILLIONS, % OF TOTAL)
TABLE 5 LARGEST PHARMACEUTICAL MARKETS (BRANDED), 2006
AND 2007 ($ BILLIONS, % OF TOTAL)
TABLE 6 WORLDWIDE LEADING PHARMACEUTICAL LARGEST
PHARMACEUTICAL MARKETS (GENERIC), 2006 AND 2007
($ BILLIONS, % OF TOTAL)
TABLE 7 LARGEST PHARMACEUTICAL MARKETS (OTC), 2006 AND
2007 ($ BILLIONS, % OF TOTAL)
TABLE 8 OVERALL PHARMACEUTICAL MARKET, U.S., THROUGH
2013 ($ BILLIONS)
TABLE 9 POPULATION TRENDS, U.S., THROUGH 2013 (MILLIONS)
TABLE 10 DEMOGRAPHIC TRENDS, U.S., THROUGH 2013 (MILLIONS)
TABLE 11 HEALTHCARE EXPENDITURE, U.S., 2000 AND 2006
TABLE 12 MOST EXPENSIVE MEDICAL CONDITIONS, U.S., 2004
($ BILLIONS, %)
TABLE 13 PRESCRIPTION DRUG EXPENDITURES BY CATEGORY, 2006
($ BILLIONS)
TABLE 14 LEADING CAUSES OF DEATH, U.S. 1997-2005 (%)
TABLE 15 CARDIOVASCULAR DISEASE, U.S., 2005 (%)
TABLE 16 INVASIVE CANCER, U.S., 2004 (%)
TABLE 17 CANCER DEATHS, U.S., 2004 (%)
TABLE 18 CANCER DEATHS, U.S., 2004 (RATIO OF DEATHS: NEW
CASES)
TABLE 19 NEW MOLECULAR ENTITIES APPROVED BY THE FDA,
1980 TO MARCH 20, 2007
TABLE 20 NME APPROVALS BY DISORDER, 2004-MARCH 20, 2008
TABLE 21 BOTOX SALES, 1993-2012 ($ MILLIONS)
TABLE 22 MARKET SHARE: PHARMACY BENEFIT MANAGERS, 2007
(%)
TABLE 23 MARKET SHARE: U.S. WHOLESALERS, 2007 (%, $ BILLIONS)
TABLE 24 LEADING DRUG RETAILERS RX VOLUME, U.S., 2002 AND
2007 (RX MILLIONS)
TABLE 25 EXPORT-IMPORT PROFILE, U.S., 1995-2006 ($ BILLIONS)
TABLE 26 BRANDED PHARMACEUTICAL MARKET, U.S., THROUGH
2013 ($ BILLIONS)
TABLE 27 TOP 10 SELLING U.S. DRUGS, 2006 AND 2007 ($ BILLIONS)
TABLE 28 GENERIC PRESCRIPTION PHARMACEUTICAL MARKET,
U.S., THROUGH 2013 ($ BILLIONS)
TABLE 29 OTC PHARMACEUTICAL MARKET, U.S., THROUGH 2013
($ BILLIONS)
TABLE 30 OVERALL PHARMACEUTICAL MARKET, CANADA,
THROUGH 2013 ($ BILLIONS)
TABLE 31 POPULATION TRENDS, CANADA, THROUGH 2013
(MILLIONS)
TABLE 32 DEMOGRAPHIC TRENDS, CANADA, THROUGH 2013
(MILLIONS)
TABLE 33 HEALTHCARE EXPENDITURE: CANADA, 2000 AND 2005
TABLE 34 BRANDED PHARMACEUTICAL MARKET, CANADA,
THROUGH 2013 ($ BILLIONS)
TABLE 35 GENERIC PHARMACEUTICAL MARKET, CANADA,
THROUGH 2013 ($ BILLIONS)
TABLE 36 OTC PHARMACEUTICAL MARKET, CANADA, THROUGH
2013 ($ BILLIONS)
TABLE 37 TOP SELLING CATEGORIES OF OTC MEDICATIONS IN
CANADA (%)
TABLE 38 OVERALL PHARMACEUTICAL MARKET, MEXICO,
THROUGH 2013 ($ BILLIONS)
TABLE 39 POPULATION TRENDS, MEXICO, THROUGH 2013
(MILLIONS)
TABLE 40 HEALTHCARE EXPENDITURE: MEXICO, 2000-2005
TABLE 41 BRANDED PHARMACEUTICAL MARKET, MEXICO,
THROUGH 2013 ($ BILLIONS)
TABLE 42 GENERIC PHARMACEUTICAL MARKET, MEXICO,
THROUGH 2013 ($ BILLIONS)
TABLE 43 OTC PHARMACEUTICAL MARKET, MEXICO, THROUGH
2013 ($ BILLIONS)
TABLE 44 OVERALL PHARMACEUTICAL MARKET, BRAZIL,
THROUGH 2013 ($ BILLIONS)
TABLE 45 POPULATION TRENDS, BRAZIL, THROUGH 2013
(MILLIONS)
TABLE 46 BRANDED PHARMACEUTICAL MARKET, BRAZIL,
THROUGH 2013 ($ BILLIONS)
TABLE 47 GENERIC PHARMACEUTICAL MARKET, BRAZIL, THROUGH
2013 ($ BILLIONS)
TABLE 48 OTC PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013
($ MILLIONS)
TABLE 49 TOP FIVE PHARMACEUTICAL MARKETS, EUROPE,
THROUGH 2013 ($ BILLIONS)
TABLE 50 BRANDED PRESCRIPTION PHARMACEUTICALS MARKET
BY VALUE, EUROPE, THROUGH 2013 ($ BILLIONS)
TABLE 51 GENERIC PHARMACEUTICALS MARKET BY VALUE,
EUROPE, THROUGH 2013 ($ BILLIONS)
TABLE 52 OTC PHARMACEUTICALS MARKET BY VALUE, EUROPE,
THROUGH 2013 ($ BILLIONS)
TABLE 53 OVERALL PHARMACEUTICAL MARKET, FRANCE,
THROUGH 2013 ($ BILLIONS)
TABLE 54 POPULATION TRENDS, FRANCE, THROUGH 2013
(MILLIONS)
TABLE 55 DEMOGRAPHIC TRENDS, FRANCE, THROUGH 2013
(MILLIONS)
TABLE 56 HEALTHCARE EXPENDITURE: FRANCE, 2000-2005
TABLE 57 DEMENTIA IN FRANCE, 2005-2050 (MILLIONS OF PEOPLE)
TABLE 58 PERCENTAGE OF SPENDING ON PHARMACEUTICALS BY
CLASS, FRANCE, 2006 (%)
TABLE 59 BRANDED PHARMACEUTICAL MARKET, FRANCE,
THROUGH 2013 ($ BILLIONS)
TABLE 60 GENERIC PHARMACEUTICAL MARKET, FRANCE,
THROUGH 2013 ($ BILLIONS)
TABLE 61 OTC PHARMACEUTICAL MARKET, FRANCE, THROUGH
2013 ($ BILLIONS)
TABLE 62 REASONS FOR ADULT PURCHASES OF OTC MEDICATIONS
IN FRANCE (%)
TABLE 63 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006
($ BILLIONS)
TABLE 64 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006
($ BILLIONS)
TABLE 65 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006
(EUROS, MILLIONS)
TABLE 66 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006
(EUROS, MILLIONS)
TABLE 67 OVERALL PHARMACEUTICAL MARKET, GERMANY,
THROUGH 2013 ($ BILLIONS)
TABLE 68 POPULATION TRENDS, GERMANY, THROUGH 2013
(MILLIONS)
TABLE 69 DEMOGRAPHIC TRENDS, GERMANY, THROUGH 2013
(MILLIONS)
TABLE 70 HEALTHCARE EXPENDITURE: GERMANY, 2000-2005
TABLE 71 DEMENTIA IN GERMANY, 2005-2050 (MILLIONS OF
PEOPLE)
TABLE 72 EXPENDITURES BY THERAPY AREA, GERMANY
(PERCENTAGE OF HEALTHCARE SPENDING, ROUNDED)
TABLE 73 BRANDED PHARMACEUTICAL MARKET, GERMANY,
THROUGH 2013 ($ BILLIONS)
TABLE 74 GENERIC PHARMACEUTICAL MARKET, GERMANY,
THROUGH 2013 ($ BILLIONS)
TABLE 75 OTC PHARMACEUTICAL MARKET, GERMANY, THROUGH
2013 ($ BILLIONS)
TABLE 76 LEADING OTC PRODUCTS, GERMANY, 2006 (%)
TABLE 77 PHARMACEUTICAL EXPORTS, GERMANY, 2005 AND 2006
(EUROS, MILLIONS)
TABLE 78 PHARMACEUTICAL IMPORTS, GERMANY, 2005 AND 2006
(EUROS, MILLIONS)
TABLE 79 OVERALL PHARMACEUTICAL MARKET, U.K., THROUGH
2013 ($ BILLIONS)
TABLE 80 POPULATION TRENDS, U.K., THROUGH 2013 (MILLIONS)
TABLE 81 DEMOGRAPHIC TRENDS, U.K., THROUGH 2013 (MILLIONS)
TABLE 82 HEALTHCARE EXPENDITURE: U.K., 2000-2005
TABLE 83 PREVALENCE OF DEMENTIA IN THE U.K. 2005-2050
(MILLIONS OF PEOPLE)
TABLE 84 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS
BY TOP EIGHT CLASSES, U.K., 2006 (%)
TABLE 85 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS,
BY CLASS, U.K., 2006 ($ MILLIONS)
TABLE 86 BRANDED PHARMACEUTICAL MARKET, U.K., THROUGH
2013 ($ BILLIONS)
TABLE 87 LEADING PHARMACEUTICAL COMPANIES, U.K., 2004
(% OF TOTAL MARKET)
TABLE 88 GENERIC PHARMACEUTICAL MARKET, U.K., THROUGH
2013 ($ BILLIONS)
TABLE 89 OTC PHARMACEUTICAL MARKET, U.K., THROUGH 2013
($ BILLIONS)
TABLE 90 LEADING OTC CATEGORIES, 2006, U.K. (% OF TOTAL
MARKET)
TABLE 91 PHARMACEUTICAL EXPORTS-IMPORTS, U.K., 1997-2006
($ BILLIONS)
TABLE 92 LEADING PHARMACEUTICAL DISTRIBUTORS, U.K. (% OF
TOTAL MARKET)
TABLE 93 PHARMACEUTICAL EXPORTS, U.K., 1997-2006 (£ BILLIONS)
TABLE 94 OVERALL PHARMACEUTICAL MARKET, ITALY, THROUGH
2013 ($ BILLIONS)
TABLE 95 POPULATION TRENDS, ITALY, THROUGH 2013 (MILLIONS)
TABLE 96 DEMOGRAPHIC TRENDS, ITALY, THROUGH 2013
(MILLIONS)
TABLE 97 HEALTHCARE EXPENDITURE: ITALY, 2000-2005
TABLE 98 PERCENTAGE OF CLASS C PRESCRIPTION
PHARMACEUTICALS BY CLASS, ITALY, 2006 (%)
TABLE 99 BRANDED PHARMACEUTICAL MARKET, ITALY, THROUGH
2013 ($ BILLIONS)
TABLE 100 GENERIC PHARMACEUTICAL MARKET, ITALY, THROUGH
2013 ($ BILLIONS)
TABLE 101 OTC PHARMACEUTICAL MARKET, ITALY, THROUGH 2013
($ BILLIONS)
TABLE 102 LEADING OTC CATEGORIES, ITALY, 2006 (% OF TOTAL
MARKET)
TABLE 103 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006
($ BILLIONS, ROUNDED)
TABLE 104 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL
EXPORTS, 2006 (% OF TOTAL MARKET)
TABLE 105 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006
($ BILLIONS)
TABLE 106 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL
IMPORTS, 2006 (% OF TOTAL MARKET)
TABLE 107 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006
(€ BILLIONS)
TABLE 108 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006
(€ BILLIONS)
TABLE 109 OVERALL PHARMACEUTICAL MARKET, SPAIN, THROUGH
2013 ($ BILLIONS)
TABLE 110 POPULATION TRENDS, SPAIN, THROUGH 2013
(MILLIONS)
TABLE 111 DEMOGRAPHIC TRENDS, SPAIN, THROUGH 2013
(MILLIONS)
TABLE 112 HEALTHCARE EXPENDITURE: SPAIN, 2000-2005
TABLE 113 PERCENTAGE OF PRESCRIPTION OF
PHARMACEUTICALS, BY CLASS, SPAIN, 2006
TABLE 114 BRANDED PHARMACEUTICAL MARKET, SPAIN,
THROUGH 2013 ($ BILLIONS)
TABLE 115 GENERIC PHARMACEUTICAL MARKET, SPAIN, THROUGH
2013 ($ BILLIONS)
TABLE 116 OTC PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013
($ MILLIONS)
TABLE 117 PHARMACEUTICAL EXPORTS, SPAIN, 2005 AND 2006 (%)
TABLE 118 PHARMACEUTICAL IMPORTS, SPAIN, 2005 AND 2006 (%)
TABLE 119 OVERALL PHARMACEUTICAL MARKET, GREECE,
THROUGH 2013 ($ BILLIONS)
TABLE 120 POPULATION TRENDS, GREECE, THROUGH 2013
(MILLIONS)
TABLE 121 DEMOGRAPHIC TRENDS, GREECE, THROUGH 2013
(MILLIONS)
TABLE 122 HEALTHCARE EXPENDITURE: GREECE, 2000-2005
TABLE 123 PERCENTAGE OF PRESCRIPTION PHARMACEUTICALS,
BY CLASS, GREECE, 2004
TABLE 124 BRANDED PHARMACEUTICAL MARKET, GREECE,
THROUGH 2013 ($ BILLIONS)
TABLE 125 GENERIC PHARMACEUTICAL MARKET, GREECE,
THROUGH 2013 ($ BILLIONS)
TABLE 126 OTC PHARMACEUTICAL MARKET, GREECE, THROUGH
2013 ($ MILLIONS)
TABLE 127 LEADING OTC CATEGORIES, GREECE, 2006 (% OF TOTAL
MARKET)
TABLE 128 OVERALL PHARMACEUTICAL MARKET, NETHERLANDS,
THROUGH 2013 ($ BILLIONS)
TABLE 129 POPULATION TRENDS, NETHERLANDS, THROUGH 2013
(MILLIONS)
TABLE 130 DEMOGRAPHIC TRENDS, NETHERLANDS, THROUGH 2013
(MILLIONS)
TABLE 131 HEALTHCARE EXPENDITURE: THE NETHERLANDS, 2000-
2005
TABLE 132 BRANDED PHARMACEUTICAL MARKET, NETHERLANDS,
THROUGH 2013 ($ BILLIONS)
TABLE 133 GENERIC PHARMACEUTICAL MARKET, NETHERLANDS,
THROUGH 2013 ($ BILLIONS)
TABLE 134 OTC PHARMACEUTICAL MARKET, NETHERLANDS,
THROUGH 2013 ($ MILLIONS)
TABLE 135 LEADING OTC CATEGORIES, NETHERLANDS, 2006 (% OF
TOTAL MARKET)
TABLE 136 OVERALL PHARMACEUTICAL MARKET, BELGIUM,
THROUGH 2013 ($ BILLIONS)
TABLE 137 POPULATION TRENDS, BELGIUM, THROUGH 2013
(MILLIONS)
TABLE 138 DEMOGRAPHIC TRENDS, BELGIUM, THROUGH 2013
(MILLIONS)
TABLE 139 HEALTHCARE EXPENDITURE: BELGIUM, 2000-2005
TABLE 140 BRANDED PHARMACEUTICAL MARKET, BELGIUM,
THROUGH 2013 ($ BILLIONS)
TABLE 141 GENERIC PHARMACEUTICAL MARKET, BELGIUM,
THROUGH 2013 ($ BILLIONS)
TABLE 142 OTC PHARMACEUTICAL MARKET, BELGIUM, THROUGH
2013 ($ MILLIONS)
TABLE 143 LEADING OTC CATEGORIES, BELGIUM, 2006 (% OF TOTAL
MARKET)
TABLE 144 OVERALL PHARMACEUTICAL MARKET, POLAND,
THROUGH 2013 ($ BILLIONS)
TABLE 145 POPULATION TRENDS, POLAND, THROUGH 2013
(MILLIONS)
TABLE 146 DEMOGRAPHIC TRENDS, POLAND, THROUGH 2013
(MILLIONS)
TABLE 147 HEALTHCARE EXPENDITURE: POLAND, 2000-2005
TABLE 148 BRANDED PHARMACEUTICAL MARKET, POLAND,
THROUGH 2013 ($ BILLIONS)
TABLE 149 GENERIC PHARMACEUTICAL MARKET, POLAND,
THROUGH 2013 ($ BILLIONS)
TABLE 150 OTC PHARMACEUTICAL MARKET, POLAND, THROUGH
2013 ($ MILLIONS)
TABLE 151 LEADING OTC CATEGORIES, POLAND, 2006 (% OF TOTAL
MARKET)
TABLE 152 OVERALL PHARMACEUTICAL MARKET, PORTUGAL,
THROUGH 2013 ($ BILLIONS)
TABLE 153 POPULATION TRENDS, PORTUGAL, THROUGH 2013
(MILLIONS)
TABLE 154 DEMOGRAPHIC TRENDS, PORTUGAL, THROUGH 2013
(MILLIONS)
TABLE 155 HEALTHCARE EXPENDITURE: PORTUGAL, 2000-2005
TABLE 156 BRANDED PHARMACEUTICAL MARKET, PORTUGAL,
THROUGH 2013 ($ BILLIONS)
TABLE 157 GENERIC PHARMACEUTICAL MARKET, PORTUGAL,
THROUGH 2013 ($ BILLIONS)
TABLE 158 OTC PHARMACEUTICAL MARKET, PORTUGAL, THROUGH
2013 ($ MILLIONS)
TABLE 159 LEADING OTC CATEGORIES, PORTUGAL, 2006 (% OF
TOTAL MARKET)
TABLE 160 OVERALL PHARMACEUTICAL MARKET, SWITZERLAND,
THROUGH 2013 ($ BILLIONS)
TABLE 161 POPULATION TRENDS, SWITZERLAND, THROUGH 2013
(MILLIONS)
TABLE 162 DEMOGRAPHIC TRENDS, SWITZERLAND, THROUGH 2013
(MILLIONS)
TABLE 163 HEALTHCARE EXPENDITURE: SWITZERLAND, 2000-2005
TABLE 164 BRANDED PHARMACEUTICAL MARKET, SWITZERLAND,
THROUGH 2013 ($ BILLIONS)
TABLE 165 GENERIC PHARMACEUTICAL MARKET, SWITZERLAND,
THROUGH 2013 ($ BILLIONS)
TABLE 166 OTC PHARMACEUTICAL MARKET, SWITZERLAND,
THROUGH 2013 ($ MILLIONS)
TABLE 167 LEADING OTC CATEGORIES, SWITZERLAND, 2006 (% OF
TOTAL MARKET)
TABLE 168 OVERALL PHARMACEUTICAL MARKET, SWEDEN,
THROUGH 2013 ($ BILLIONS)
TABLE 169 POPULATION TRENDS, SWEDEN, THROUGH 2013
(MILLIONS)
TABLE 170 DEMOGRAPHIC TRENDS, SWEDEN, THROUGH 2013
(MILLIONS)
TABLE 171 HEALTHCARE EXPENDITURE: SWEDEN, 2000-2005
TABLE 172 LEADING THERAPEUTIC CATEGORIES, SWEDEN, 2006
(% OF TOTAL MARKET, BY VALUE)
TABLE 173 BRANDED PHARMACEUTICAL MARKET, SWEDEN,
THROUGH 2013 ($ BILLIONS)
TABLE 174 GENERIC PHARMACEUTICAL MARKET, SWEDEN,
THROUGH 2013 ($ BILLIONS)
TABLE 175 OTC PHARMACEUTICAL MARKET, SWEDEN, THROUGH
2013 ($ MILLIONS)
TABLE 176 OVERALL PHARMACEUTICAL MARKET, AUSTRIA,
THROUGH 2013 ($ BILLIONS)
TABLE 177 POPULATION TRENDS, AUSTRIA, THROUGH 2013
(MILLIONS)
TABLE 178 DEMOGRAPHIC TRENDS, AUSTRIA, THROUGH 2013
(MILLIONS)
TABLE 179 HEALTHCARE EXPENDITURE: AUSTRIA, 2000-2005
TABLE 180 BRANDED PHARMACEUTICAL MARKET, AUSTRIA,
THROUGH 2013 ($ BILLIONS)
TABLE 181 GENERIC PHARMACEUTICAL MARKET, AUSTRIA,
THROUGH 2013 ($ BILLIONS)
TABLE 182 OTC PHARMACEUTICAL MARKET, AUSTRIA, THROUGH
2013 ($ MILLIONS)
TABLE 183 OVERALL PHARMACEUTICAL MARKET, HUNGARY,
THROUGH 2013 ($ BILLIONS)
TABLE 184 BRANDED PHARMACEUTICAL MARKET, HUNGARY,
THROUGH 2013 ($ BILLIONS)
TABLE 185 GENERIC PHARMACEUTICAL MARKET, HUNGARY,
THROUGH 2013 ($ BILLIONS)
TABLE 186 OTC PHARMACEUTICAL MARKET, HUNGARY, THROUGH
2013 ($ MILLIONS)
TABLE 187 OVERALL PHARMACEUTICAL MARKET, FINLAND,
THROUGH 2013 ($ BILLIONS)
TABLE 188 POPULATION TRENDS, FINLAND, THROUGH 2013
(MILLIONS)
TABLE 189 DEMOGRAPHIC TRENDS, FINLAND, THROUGH 2013
(MILLIONS)
TABLE 190 LEADING THERAPEUTIC CATEGORIES, FINLAND, 2006
(% OF TOTAL MARKET, BY VALUE)
TABLE 191 BRANDED PHARMACEUTICAL MARKET, FINLAND,
THROUGH 2013 ($ BILLIONS)
TABLE 192 GENERIC PHARMACEUTICAL MARKET, FINLAND,
THROUGH 2013 ($ BILLIONS)
TABLE 193 OTC PHARMACEUTICAL MARKET, FINLAND, THROUGH
2013 ($ MILLIONS)
TABLE 194 OVERALL PHARMACEUTICAL MARKET, JAPAN,
THROUGH 2013 ($ BILLIONS)
TABLE 195 POPULATION TRENDS, JAPAN, THROUGH 2013
(MILLIONS)
TABLE 196 DEMOGRAPHIC TRENDS, JAPAN, THROUGH 2013
(MILLIONS)
TABLE 197 HEALTHCARE EXPENDITURE: JAPAN, 2000-2005
TABLE 198 LEADING CAUSES OF DEATH, JAPAN, 2005
TABLE 199 LEADING FORMS OF CANCER, JAPAN, 2005
TABLE 120 BRANDED PHARMACEUTICAL MARKET, JAPAN,
THROUGH 2013 ($ BILLIONS)
TABLE 201 GENERIC PHARMACEUTICAL MARKET, JAPAN,
THROUGH 2013 ($ BILLIONS)
TABLE 202 OTC PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013
($ BILLIONS)
TABLE 203 LEADING OTC CATEGORIES, JAPAN
TABLE 204 OVERALL PHARMACEUTICAL MARKET, CHINA,
THROUGH 2013 ($ BILLIONS)
TABLE 205 POPULATION TRENDS, CHINA, THROUGH 2013
(MILLIONS)
TABLE 206 DEMOGRAPHIC TRENDS, CHINA, THROUGH 2013
(MILLIONS)
TABLE 207 PRESCRIPTION PHARMACEUTICAL MARKET, CHINA,
THROUGH 2013 ($ BILLIONS)
TABLE 208 OTC PHARMACEUTICAL MARKET, CHINA, THROUGH 2013
($ MILLIONS)
TABLE 209 OVERALL PHARMACEUTICAL MARKET, SOUTH KOREA,
THROUGH 2013 ($ BILLIONS)
TABLE 210 POPULATION TRENDS, SOUTH KOREA, THROUGH 2013
(MILLIONS)
TABLE 211 DEMOGRAPHIC TRENDS, SOUTH KOREA, THROUGH 2013
(MILLIONS)
TABLE 212 LEADING CAUSES OF DEATH, SOUTH KOREA, 2003
TABLE 213 PRESCRIPTION PHARMACEUTICAL MARKET, SOUTH
KOREA, THROUGH 2013 ($ BILLIONS)
TABLE 214 OTC PHARMACEUTICAL MARKET, SOUTH KOREA,
THROUGH 2013 ($ MILLIONS)
TABLE 215 OVERALL PHARMACEUTICAL MARKET, AUSTRALIA,
THROUGH 2013 ($ BILLIONS)
TABLE 216 POPULATION TRENDS, AUSTRALIA, THROUGH 2013
(MILLIONS)
TABLE 217 LEADING CAUSES OF DEATH, MEN, AUSTRALIA, 2005
(% OF ALL DEATHS)
TABLE 218 LEADING CAUSES OF DEATH, WOMEN, AUSTRALIA, 2004
(% OF ALL DEATHS)
TABLE 219 COMMON CHRONIC CONDITIONS, AUSTRALIA, 2005 (% OF
POPULATION)
TABLE 220 BRANDED PHARMACEUTICAL MARKET, AUSTRALIA,
THROUGH 2013 ($ BILLIONS)
TABLE 221 GENERIC PHARMACEUTICAL MARKET, AUSTRALIA,
THROUGH 2013 ($ BILLIONS)
TABLE 222 OTC PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH
2013 ($ MILLIONS)
TABLE 223 TOP OTC PURCHASES, AUSTRALIA (% OF THE
POPULATION)
TABLE 224 OVERALL PHARMACEUTICAL MARKET, INDIA, THROUGH
2013 ($ BILLIONS)
TABLE 225 POPULATION TRENDS, INDIA, THROUGH 2013
(MILLIONS)
TABLE 226 TOP INDIAN PHARMACEUTICAL COMPANIES BY
REVENUES, 2006 ($ MILLIONS)
TABLE 227 PRESCRIPTION PHARMACEUTICAL MARKET, INDIA,
THROUGH 2013 ($ BILLIONS)
TABLE 228 OTC PHARMACEUTICAL MARKET, INDIA, THROUGH 2013
($ BILLIONS)
LIST OF FIGURES
SUMMARY FIGURE WORLDWIDE MARKET PHARMACEUTICAL
PRODUCTS, 2006-2013 ($ BILLIONS)
FIGURE 1 U.S. POPULATION, 1998-2013 (MILLIONS)
FIGURE 2 U.S. HEALTHCARE EXPENDITURES, 1980-2006
($ BILLIONS)
FIGURE 3 NME APPROVALS, 1997-2007
FIGURE 4 NME APPROVALS IN TWO SEVEN-YEAR PERIODS, 1994-
2007
FIGURE 5 CANADA: POPULATION 1998-2013 (MILLIONS)
FIGURE 6 FRANCE: POPULATION, 1998-2013 (MILLIONS)
FIGURE 7 VALUE BREAKDOWN OF PHARMACEUTICALS, FRANCE,
2005 (%)
FIGURE 8 LEADING GENERIC MANUFACTURERS, MARKET SHARE,
FRANCE, 2006 (% SHARE)
FIGURE 9 LEADING WHOLESALERS MARKET SHARE, FRANCE, 2006-
2007 (% SHARE)
FIGURE 10 GERMANY: POPULATION 1998-2013 (MILLIONS)
FIGURE 11 VALUE BREAKDOWN OF PHARMACEUTICALS, GERMANY,
2005 (%)
FIGURE 12 LEADING WHOLESALERS MARKET SHARE, GERMANY,
2006-2007 (% SHARE)
FIGURE 13 U.K. POPULATION, 1998-2013 (MILLIONS)
FIGURE 14 ITALY: POPULATION, 1998-2013 (MILLIONS)
FIGURE 15 VALUE BREAKDOWN OF PHARMACEUTICALS, ITALY,
2005 (%)
FIGURE 16 SPAIN: POPULATION, 1998-2013 (MILLIONS)
FIGURE 17 VALUE BREAKDOWN OF PHARMACEUTICALS, SPAIN,
2005 (%)
FIGURE 18 GREECE: POPULATION, 1998-2013
(MILLIONS)
FIGURE 19 VALUE BREAKDOWN OF PHARMACEUTICALS, GREECE,
2005 (%)
FIGURE 20 NETHERLANDS: POPULATION, 1998-2013 (MILLIONS)
FIGURE 21 VALUE BREAKDOWN OF PHARMACEUTICALS,
NETHERLANDS, 2005 (%)
FIGURE 22 BELGIUM: POPULATION, 1998-2013 (MILLIONS)
FIGURE 23 VALUE BREAKDOWN OF PHARMACEUTICALS, BELGIUM,
2005 (%)
FIGURE 24 POLAND: POPULATION, 1998-2013 (MILLIONS)
FIGURE 25 PORTUGAL: POPULATION, 1998-2013 (MILLIONS)
FIGURE 26 VALUE BREAKDOWN OF PHARMACEUTICALS,
PORTUGAL, 2005 (%)
FIGURE 27 SWITZERLAND: POPULATION, 1998-2013 (MILLIONS)
FIGURE 28 VALUE BREAKDOWN OF PHARMACEUTICALS,
SWITZERLAND, 2005 (%)
FIGURE 29 SWEDEN: POPULATION, 1998-2013 (MILLIONS)
FIGURE 30 VALUE BREAKDOWN OF PHARMACEUTICALS, SWEDEN,
2005 (%)
FIGURE 31 AUSTRIA: POPULATION, 1998-2013 (MILLIONS)
FIGURE 32 JAPAN: POPULATION, 1998-2013 (MILLIONS)
Top of Page
Table of Contents
INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
AUDIENCE FOR THE REPORT
SCOPE AND FORMAT
METHODOLOGY AND INFORMATION SOURCES
BCC INFORMATION AND RELATED BCC STUDIES
AUTHOR’S CREDENTIALS
BCC ONLINE SERVICES
DISCLAIMER
SUMMARY
AGING POPULATIONS AND CHRONIC DISEASES
OVERALL GLOBAL PHARMACEUTICAL MARKETS
SUMMARY TABLE WORLDWIDE MARKET PHARMACEUTICAL PRODUCTS, THROUGH 2013 ($ BILLIONS)
SUMMARY FIGURE WORLDWIDE MARKET PHARMACEUTICAL PRODUCTS, 2006-2013 ($ BILLIONS)
OVERVIEW
BACKGROUND ON THE INDUSTRY
RECENT HISTORY
BENEFITS, PROBLEMS, AND REGULATION
CHANGES IN THE INDUSTRY
HEALTHCARE EXPENDITURES
TABLE 1 HEALTHCARE EXPENDITURES, COUNTRIES IN THIS REPORT, 2000 AND 2005 (% OF GDP)
THE PHARMACEUTICAL INDUSTRY
TABLE 2 WORLDWIDE LEADING ETHICAL PHARMACEUTICAL COMPANIES: SALES AND MARKET SHARE, 2006 AND 2007 ($ BILLIONS)
RESEARCH AND DEVELOPMENT EXPENDITURES
TABLE 3 WORLDWIDE LEADING PHARMACEUTICAL COMPANIES BY R&D SPENDING, 2006 AND 2007 ($ BILLIONS)
SECTOR PERFORMANCE
BRANDED PHARMACEUTICALS
TABLE 4 LARGEST PHARMACEUTICAL MARKETS (OVERALL), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)
TABLE 5 LARGEST PHARMACEUTICAL MARKETS (BRANDED), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)
TABLE 6 WORLDWIDE LEADING PHARMACEUTICAL LARGEST PHARMACEUTICAL MARKETS (GENERIC), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)
TABLE 7 LARGEST PHARMACEUTICAL MARKETS (OTC), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)
UNITED STATES
INTRODUCTION
TABLE 8 OVERALL PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 9 POPULATION TRENDS, U.S., THROUGH 2013 (MILLIONS)
FIGURE 1 U.S. POPULATION, 1998-2013 (MILLIONS)
TABLE 10 DEMOGRAPHIC TRENDS, U.S., THROUGH 2013 (MILLIONS)
THE U.S. HEALTHCARE SYSTEM
HEALTHCARE EXPENDITURES IN THE U.S
FIGURE 2 U.S. HEALTHCARE EXPENDITURES, 1980-2006 ($ BILLIONS)
TABLE 11 HEALTHCARE EXPENDITURE, U.S., 2000 AND 2006
TABLE 12 MOST EXPENSIVE MEDICAL CONDITIONS, U.S., 2004 ($ BILLIONS, %)
TABLE 13 PRESCRIPTION DRUG EXPENDITURES BY CATEGORY, 2006 ($ BILLIONS)
COMMON HEALTH PROBLEMS IN THE U.S.
TABLE 14 LEADING CAUSES OF DEATH, U.S. 1997-2005 (%)
ALZHEIMER’S DISEASE (AD) AND RELATED DEMENTIAS
OBESITY AND RELATED CONDITIONS
DIABETES
CARDIOVASCULAR DISEASE
TABLE 15 CARDIOVASCULAR DISEASE, U.S., 2005 (%)
SMOKING
CANCER
TABLE 16 INVASIVE CANCER, U.S., 2004 (%)
TABLE 16 (CONTINUED)
TABLE 17 CANCER DEATHS, U.S., 2004 (%)
TABLE 18 CANCER DEATHS, U.S., 2004 (RATIO OF DEATHS: NEW CASES)
HIV INFECTION
GOVERNMENT REGULATIONS
INTRODUCTION
DRUG DISCOVERY
Preclinical Testing and Submission of an IND
CLINICAL TRIALS
TIMELINE AND COSTS
SUBMISSION OF AN NDA OR BLA
POST-FDA APPROVAL
NEW DRUG APPROVALS
FIGURE 3 NME APPROVALS, 1997-2007
FIGURE 4 NME APPROVALS IN TWO SEVEN-YEAR PERIODS, 1994-2007
TABLE 19 NEW MOLECULAR ENTITIES APPROVED BY THE FDA, 1980 TO MARCH 20, 2007
DO CURRENT CORPORATE MANAGEMENT PRACTICES HAVE A ROLE IN R&D SHORTFALLS?
BLOCKBUSTER DRUGS
TABLE 20 NME APPROVALS BY DISORDER, 2004-MARCH 20, 2008
OTHER SUCCESSFUL THERAPEUTIC AGENTS
TABLE 21 BOTOX SALES, 1993-2012 ($ MILLIONS)
IS THE NIH FUNDING CRISIS CONTRIBUTING TO SHORTFALLS IN DRUG DISCOVERY?
PHARMACEUTICAL PRICING
FACTORS AFFECTING DRUG PRICES
PHARMACY BENEFIT MANAGERS (PBMS)
TABLE 22 MARKET SHARE: PHARMACY BENEFIT MANAGERS, 2007 (%)
Pharmacy Benefit Managers ? (Continued)
PHARMACEUTICAL FLOW FROM MANUFACTURER TO PATIENT
PHARMACEUTICAL WHOLESALING
TABLE 23 MARKET SHARE: U.S. WHOLESALERS, 2007 (%, $ BILLIONS)
PHARMACEUTICAL RETAILING
TABLE 24 LEADING DRUG RETAILERS RX VOLUME, U.S., 2002 AND 2007 (RX MILLIONS)
EXPORT-IMPORT PROFILE
TABLE 25 EXPORT-IMPORT PROFILE, U.S., 1995-2006 ($ BILLIONS)
MARKET SECTORS
BRANDED PRESCRIPTION PHARMACEUTICALS
TABLE 26 BRANDED PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)
TABLE 27 TOP 10 SELLING U.S. DRUGS, 2006 AND 2007 ($ BILLIONS)
GENERIC DRUGS
TABLE 28 GENERIC PRESCRIPTION PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)
OVER-THE-COUNTER (OTC) MEDICATIONS IN THE U.S.
TABLE 29 OTC PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)
IMPORTANT ORGANIZATIONS IN THE U.S
PHRMA, THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
GPHA, GENERIC PHARMACEUTICAL ASSOCIATION
CHPA (CONSUMER HEALTHCARE PRODUCTS ASSOCIATION)
COMPANY PROFILES: UNITED STATES
ABBOTT LABORATORIES
BIOGEN IDEC
AMGEN
BRISTOL-MYERS SQUIBB
FOREST LABORATORIES
GENENTECH
GENZYME
JOHNSON & JOHNSON
ELI LILLY AND COMPANY
MERCK & CO. INC
PFIZER
WYETH PHARMACEUTICALS
TEVA PHARMACEUTICALS
Teva North America
CANADA
INTRODUCTION
TABLE 30 OVERALL PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 31 POPULATION TRENDS, CANADA, THROUGH 2013 (MILLIONS)
FIGURE 5 CANADA: POPULATION 1998-2013 (MILLIONS)
TABLE 32 DEMOGRAPHIC TRENDS, CANADA, THROUGH 2013 (MILLIONS)
THE CANADIAN HEALTHCARE SYSTEM
HEALTHCARE EXPENDITURE IN CANADA
TABLE 33 HEALTHCARE EXPENDITURE: CANADA, 2000 AND 2005
COMMON HEALTH PROBLEMS IN CANADA
ALZHEIMER’S DISEASE AND RELATED DEMENTIAS
OBESITY AND RELATED CONDITIONS
DIABETES
CARDIOVASCULAR DISEASE AND CANCER
HIV INFECTION
PHARMACEUTICAL PRICING
MARKET SECTORS
BRANDED PRESCRIPTION PHARMACEUTICALS
TABLE 34 BRANDED PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)
GENERIC DRUGS
TABLE 35 GENERIC PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)
OVER-THE-COUNTER (OTC) MEDICATIONS IN CANADA
TABLE 36 OTC PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)
TABLE 37 TOP SELLING CATEGORIES OF OTC MEDICATIONS IN CANADA (%)
IMPORTANT ORGANIZATIONS IN CANADA
STATISTICS CANADA
RX&D, CANADA’S RESEARCH-BASED PHARMACEUTICAL COMPANIES
CGPA (CANADIAN GENERIC PHARMACEUTICAL ASSOCIATION)
NDMAC (THE NONPRESCRIPTION DRUG MANUFACTURERS ASSOCIATION OF CANADA)
COMPANY PROFILES: CANADA
ABBOTT LABORATORIES, LIMITED
ACTELION
ASTRAZENECA CANADA INC.
BAYER, INC
BRISTOL-MYERS SQUIBB CANADA
ELI LILLY CANADA INC.
GLAXOSMITHKLINE INC.
HOFFMANN-LA ROCHE LIMITED
LUNDBECK CANADA INC.
MERCK FROSST CANADA LTD
NOVARTIS PHARMACEUTICALS CANADA INC.
PFIZER CANADA INC.
PURDUE PHARMA (1956)
SANOFI-AVENTIS CANADA
SOLVAY PHARMA INC
WYETH PHARMACEUTICALS
Wyeth Pharmaceuticals (continued)
MEXICO
INTRODUCTION
TABLE 38 OVERALL PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 39 POPULATION TRENDS, MEXICO, THROUGH 2013 (MILLIONS)
THE MEXICAN HEALTHCARE SYSTEM
HEALTHCARE EXPENDITURE IN MEXICO
TABLE 40 HEALTHCARE EXPENDITURE: MEXICO, 2000-2005
COMMON HEALTH PROBLEMS IN MEXICO
OBESITY AND RELATED CONDITIONS
DIABETES: THE LEADING CAUSE OF DEATH
HIV INFECTION
PHARMACEUTICAL REGULATION AND PRICING
MARKET SECTORS
BRANDED PRESCRIPTION PHARMACEUTICALS
TABLE 41 BRANDED PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)
GENERIC DRUGS
TABLE 42 GENERIC PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)
OVER-THE-COUNTER (OTC) MEDICATIONS IN MEXICO
TABLE 43 OTC PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)
IMPORTANT ORGANIZATIONS IN MEXICO
STATISTICS MEXICO: SISTEMAS NACIONALES ESTADÍSTICO Y DE INFORMACIÓN GEOGRÁFICA (SNEIG)
AFAMELA (ASOCIACION DE FABRICANTES DE MEDICAMENTOS DE LIBRE ACCESO AC)
AMIIF (ASOCIACIÓN MEXICANA DE INDUSTRIALES DE INVESTIGACIÓN FARMACÉUTIA A.C., MEXICAN
ASSOCIATION OF PHARMACEUTICAL COMPANIES)
CANIFARMA (CAMARA NACIONAL DE LA INDUSTRIA FARMACEUTICA)
FIFARMA, THE LATIN AMERICAN FEDERATION OF THE PHARMACEUTICAL INDUSTRY
ILAR (INDUSTRIO LATINOAERMICANA DE AUTOMEDICACION RESPONSABLE)
BRAZIL
INTRODUCTION
TABLE 44 OVERALL PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 45 POPULATION TRENDS, BRAZIL, THROUGH 2013 (MILLIONS)
HEALTHCARE AND HEALTH PROBLEMS IN BRAZIL
THE HEALTHCARE SYSTEM (MEDICARE)
PHARMACEUTICAL PRICING
HEALTH PROBLEMS IN BRAZIL
MARKET SECTORS
BRANDED PRESCRIPTION PHARMACEUTICALS
TABLE 46 BRANDED PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ BILLIONS)
GENERIC DRUGS
TABLE 47 GENERIC PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ BILLIONS)
OVER-THE-COUNTER MEDICATIONS
TABLE 48 OTC PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ MILLIONS)
IMPORTANT ORGANIZATIONS IN BRAZIL
BRAZILIAN INSTITUTE OF GEOGRAPHY AND STATISTICS
EUROPE
HEALTHCARE IN EUROPE
REIMBURSEMENT OF PHARMACEUTICALS
POPULATION DEMOGRAPHICS IN EUROPE
POPULATION GROWTH, MEDIAN AGE, AND LIFE EXPECTANCY
EXCESS WEIGHT
LIFE EXPECTANCY IN EUROPE
PHARMACEUTICAL MARKETS IN EUROPE
TABLE 49 TOP FIVE PHARMACEUTICAL MARKETS, EUROPE, THROUGH 2013 ($ BILLIONS)
PROPRIETARY PRESCRIPTION MEDICATIONS (ALSO CALLED BRANDED MEDICATIONS AND ETHICAL PHARMACEUTICALS)
TABLE 50 BRANDED PRESCRIPTION PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 ($ BILLIONS)
DATA EXCLUSIVITY
GENERIC MEDICATIONS
TABLE 51 GENERIC PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 ($ BILLIONS)
GENERIC SMALL MOLECULES
BIOSIMILARS
OVER-THE-COUNTER MEDICATIONS
TABLE 52 OTC PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 ($ BILLIONS)
FRANCE
INTRODUCTION
TABLE 53 OVERALL PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)
DRIVERS OF PHARMACEUTICAL SALES GROWTH
POPULATION AND DEMOGRAPHICS
TABLE 54 POPULATION TRENDS, FRANCE, THROUGH 2013 (MILLIONS)
FIGURE 6 FRANCE: POPULATION, 1998-2013 (MILLIONS)
TABLE 55 DEMOGRAPHIC TRENDS, FRANCE, THROUGH 2013 (MILLIONS)
HEALTHCARE EXPENDITURE IN FRANCE
TABLE 56 HEALTHCARE EXPENDITURE: FRANCE, 2000-2005
COMMON HEALTH PROBLEMS IN FRANCE
ALZHEIMER’S DISEASE AND RELATED DEMENTIAS
TABLE 57 DEMENTIA IN FRANCE, 2005-2050 (MILLIONS OF PEOPLE)
OBESITY AND RELATED CONDITIONS
DIABETES
CARDIOVASCULAR DISEASE
TABLE 58 PERCENTAGE OF SPENDING ON PHARMACEUTICALS BY CLASS, FRANCE, 2006 (%)
PHARMACEUTICAL PRICING
FIGURE 7 VALUE BREAKDOWN OF PHARMACEUTICALS, FRANCE, 2005 (%)
FIGURE 7 (CONTINUED)
MARKET SECTORS
BRANDED PRESCRIPTION PHARMACEUTICALS
TABLE 59 BRANDED PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)
GENERIC DRUGS
TABLE 60 GENERIC PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)
FIGURE 8 LEADING GENERIC MANUFACTURERS, MARKET SHARE, FRANCE, 2006 (% SHARE)
DRIVERS AND RESTRAINTS
OVER-THE-COUNTER (OTC) MEDICATIONS IN FRANCE
TABLE 61 OTC PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)
TABLE 62 REASONS FOR ADULT PURCHASES OF OTC MEDICATIONS IN FRANCE (%)
EXPORT-IMPORT PROFILE
TABLE 63 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006 ($BILLIONS)
TABLE 64 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006 ($BILLIONS)
PHARMACEUTICAL DISTRIBUTION
WHOLESALERS
FIGURE 9 LEADING WHOLESALERS MARKET SHARE, FRANCE, 2006-2007 (% SHARE)
FRANCE’S PHARMACEUTICAL EXPORTS AND IMPORTS IN
EUROS
TABLE 65 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006 (EUROS, MILLIONS)
TABLE 66 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006 (EUROS, MILLIONS)
IMPORTANT ORGANIZATIONS IN FRANCE
INSEE (NATIONAL INSTITUTE FOR STATISTICS AND ECONOMIC STUDIES)
LEEM, THE FRENCH PHARMACEUTICAL COMPANIES ASSOCIATION
CSRP (SYNDICATE OF PHARMACEUTICAL DISTRIBUTORS:
FRANCE ALZHEIMER:
COMPANY PROFILES: FRANCE
BIOGARAN
CERP
MERCK GENERIQUES
SANDOZ: (SEE GERMANY)
SANOFI-AVENTIS
Sanofi-Aventis (Continued)
GERMANY
INTRODUCTION
TABLE 67 OVERALL PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 68 POPULATION TRENDS, GERMANY, THROUGH 2013 (MILLIONS)
TABLE 69 DEMOGRAPHIC TRENDS, GERMANY, THROUGH 2013 (MILLIONS)
FIGURE 10 GERMANY: POPULATION 1998-2013 (MILLIONS)
THE GERMAN HEALTHCARE SYSTEM
HEALTHCARE EXPENDITURE IN GERMANY
TABLE 70 HEALTHCARE EXPENDITURE: GERMANY, 2000-2005
COMMON HEALTH PROBLEMS IN GERMANY
ALZHEIMER’S DISEASE AND RELATED DEMENTIAS
TABLE 71 DEMENTIA IN GERMANY, 2005-2050 (MILLIONS OF PEOPLE)
OBESITY AND RELATED CONDITIONS
DIABETES
CARDIOVASCULAR DISEASE
TABLE 72 EXPENDITURES BY THERAPY AREA, GERMANY (PERCENTAGE OF HEALTHCARE SPENDING, ROUNDED)
PRICING AND REIMBURSEMENT OF PHARMACEUTICAL AGENTS
FIGURE 11 VALUE BREAKDOWN OF PHARMACEUTICALS, GERMANY, 2005 (%)
FIGURE 11 (CONTINUED)
MARKET SECTORS
BRANDED PRESCRIPTION PHARMACEUTICALS
TABLE 73 BRANDED PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)
GENERIC DRUGS
TABLE 74 GENERIC PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)
DRIVERS AND RESTRAINTS
OVER-THE-COUNTER MEDICATIONS
TABLE 75 OTC PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)
TABLE 76 LEADING OTC PRODUCTS, GERMANY, 2006 (%)
PHARMACEUTICAL DISTRIBUTION
WHOLESALERS
FIGURE 12 LEADING WHOLESALERS MARKET SHARE, GERMANY, 2006-2007 (% SHARE)
GERMAN PHARMACEUTICAL EXPORTS AND IMPORTS IN EUROS
TABLE 77 PHARMACEUTICAL EXPORTS, GERMANY, 2005 AND 2006 (EUROS, MILLIONS)
TABLE 78 PHARMACEUTICAL IMPORTS, GERMANY, 2005 AND 2006 (EUROS, MILLIONS)
IMPORTANT ORGANIZATIONS IN GERMANY
DESTATIS (FEDERAL STATISTICAL OFFICE)
GERMAN FEDERAL MINISTRY FOR EDUCATION AND RESEARCH
DEUTSCHE DIABETES-UNION
PHARMA PRIVAT
BAH, BUNDESVERBAND DER ARZNEIMITTELHERSTELLER E.V
VFA, THE GERMAN ASSOCIATION OF RESEARCH-BASED PHARMACEUTICAL COMPANIES
COMPANY PROFILES: GERMANY
CELESIO AG
MERCK KGAA
SANDOZ
STADA ARZNEIMITTEL AG
UNITED KINGDOM (U.K.)
INTRODUCTION
TABLE 79 OVERALL PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)
DRIVERS OF PHARMACEUTICAL SALES GROWTH
POPULATION AND DEMOGRAPHICS
TABLE 80 POPULATION TRENDS, U.K., THROUGH 2013 (MILLIONS)
FIGURE 13 U.K. POPULATION, 1998-2013 (MILLIONS)
TABLE 81 DEMOGRAPHIC TRENDS, U.K., THROUGH 2013 (MILLIONS)
THE U.K. HEALTHCARE SYSTEM
HEALTHCARE EXPENDITURE IN THE U.K
TABLE 82 HEALTHCARE EXPENDITURE: U.K., 2000-2005
COMMON HEALTH PROBLEMS IN THE U.K.
ALZHEIMER’S DISEASE (AD) AND RELATED DEMENTIAS
TABLE 83 PREVALENCE OF DEMENTIA IN THE U.K. 2005-2050 (MILLIONS OF PEOPLE)
OBESITY AND RELATED CONDITIONS
DIABETES
CARDIOVASCULAR DISEASE (INCLUDING HEART DISEASE AND STROKE)
TABLE 84 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS BY TOP EIGHT CLASSES, U.K., 2006 (%)
TABLE 85 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS, BY CLASS, U.K., 2006 ($ MILLIONS)
BARRIERS TO PHARMACEUTICAL REVENUE GROWTH IN THE U.K. AND REVENUE BREAKDOWN
MARKET SECTORS
BRANDED PRESCRIPTION PHARMACEUTICALS
TABLE 86 BRANDED PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)
TABLE 87 LEADING PHARMACEUTICAL COMPANIES, U.K., 2004 (% OF TOTAL MARKET)
GENERIC DRUGS
TABLE 88 GENERIC PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)
DRIVERS AND RESTRAINTS
OVER-THE-COUNTER (OTC) MEDICATIONS IN THE U.K
TABLE 89 OTC PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)
TABLE 90 LEADING OTC CATEGORIES, 2006, U.K. (% OF TOTAL MARKET)
EXPORT-IMPORT PROFILE
TABLE 91 PHARMACEUTICAL EXPORTS-IMPORTS, U.K., 1997-2006 ($ BILLIONS)
PHARMACEUTICAL DISTRIBUTION
WHOLESALERS
TABLE 92 LEADING PHARMACEUTICAL DISTRIBUTORS, U.K. (%OF TOTAL MARKET)
U.K.’S PHARMACEUTICAL EXPORTS AND IMPORTS IN POUNDS STERLING
TABLE 93 PHARMACEUTICAL EXPORTS, U.K., 1997-2006 (£BILLIONS)
IMPORTANT ORGANIZATIONS IN THE U.K.
NATIONAL STATISTICS U.K.
ABPI, THE ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY
THE BRITISH ASSOCIATION OF PHARMACEUTICAL WHOLESALERS (BAPW)
COMPANY PROFILES: U.K
AAH PHARMACEUTICALS
GLAXOSMITHKLINE (GSK)
MAWDSLEY-BROOKS & CO. LTD.
PHOENIX HEALTHCARE DISTRIBUTION, LTD.
UNICHEM
Unichem (Continued)
ITALY
INTRODUCTION
TABLE 94 OVERALL PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)
DRIVERS OF PHARMACEUTICAL SALES GROWTH
POPULATION AND DEMOGRAPHICS
TABLE 95 POPULATION TRENDS, ITALY, THROUGH 2013 (MILLIONS)
FIGURE 14 ITALY: POPULATION, 1998-2013 (MILLIONS)
TABLE 96 DEMOGRAPHIC TRENDS, ITALY, THROUGH 2013 (MILLIONS)
THE ITALIAN HEALTHCARE SYSTEM AND GROWTH DRIVERS
TABLE 97 HEALTHCARE EXPENDITURE: ITALY, 2000-2005
COMMON HEALTH PROBLEMS IN ITALY
ALZHEIMER’S DISEASE (AD) AND RELATED DEMENTIAS
OBESITY AND RELATED CONDITIONS
DIABETES
CARDIOVASCULAR DISEASE (INCLUDING HEART DISEASE AND STROKE)
TABLE 98 PERCENTAGE OF CLASS C PRESCRIPTION PHARMACEUTICALS BY CLASS, ITALY, 2006 (%)
BARRIERS TO PHARMACEUTICAL REVENUE GROWTH IN ITALY
REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN ITALY
FIGURE 15 VALUE BREAKDOWN OF PHARMACEUTICALS, ITALY, 2005 (%)
FIGURE 15 (CONTINUED)
MARKET SECTORS
BRANDED PRESCRIPTION PHARMACEUTICALS
TABLE 99 BRANDED PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)
GENERIC DRUGS
TABLE 100 GENERIC PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)
DRIVERS AND RESTRAINTS
OVER-THE-COUNTER MEDICATIONS
TABLE 101 OTC PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)
TABLE 102 LEADING OTC CATEGORIES, ITALY, 2006 (% OF TOTAL MARKET)
EXPORT-IMPORT PROFILE
TABLE 103 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006 ($ BILLIONS, ROUNDED)
TABLE 104 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL EXPORTS, 2006 (% OF TOTAL MARKET)
TABLE 105 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006 ($ BILLIONS)
TABLE 106 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL IMPORTS, 2006 (% OF TOTAL MARKET)
ITALY’S PHARMACEUTICAL EXPORTS AND IMPORTS IN EUROS
TABLE 107 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006 (€ BILLIONS)
TABLE 108 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006 (€ BILLIONS)
IMPORTANT ORGANIZATIONS IN ITALY
NATIONAL INSTITUTE FOR STATISTICS (ISTITUTO NAZIONALE DI STATISTICA)
FARMINDUSTRIA, THE PHARMACEUTICAL MANUFACTURER’S ASSOCIATION OF ITALY
ASSOGENERICI, THE ITALIAN NATIONAL ASSOCIATION OF GENERIC PHARMACEUTICALS
SPAIN
INTRODUCTION
TABLE 109 OVERALL PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ BILLIONS)
DRIVERS OF PHARMACEUTICAL SALES GROWTH
POPULATION AND DEMOGRAPHICS
TABLE 110 POPULATION TRENDS, SPAIN, THROUGH 2013 (MILLIONS)
FIGURE 16 SPAIN: POPULATION, 1998-2013 (MILLIONS)
TABLE 111 DEMOGRAPHIC TRENDS, SPAIN, THROUGH 2013 (MILLIONS)
THE SPANISH HEALTHCARE SYSTEM, PRICING, AND PHARMACEUTICAL GROWTH DRIVERS
THE HEALTHCARE SYSTEM
TABLE 112 HEALTHCARE EXPENDITURE: SPAIN, 2000-2005
DRUG PRICING POLICIES
COMMON HEALTH PROBLEMS IN SPAIN
ALZHEIMER’S DISEASE (AD) AND RELATED DEMENTIAS
OBESITY AND RELATED CONDITIONS
DIABETES
CARDIOVASCULAR DISEASE (INCLUDING HEART DISEASE AND STROKE)
TABLE 113 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS, BY CLASS, SPAIN, 2006
GROWTH DRIVERS
BARRIERS TO PHARMACEUTICAL REVENUE GROWTH IN SPAIN
REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN SPAIN
FIGURE 17 VALUE BREAKDOWN OF PHARMACEUTICALS, SPAIN, 2005 (%)
FIGURE 17 (CONTINUED)
MARKET SECTORS
BRANDED PRESCRIPTION PHARMACEUTICALS
TABLE 114 BRANDED PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ BILLIONS)
GENERIC DRUGS
TABLE 115 GENERIC PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ BILLIONS)
DRIVERS AND RESTRAINTS
OVER-THE-COUNTER MEDICATIONS
TABLE 116 OTC PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ MILLIONS)
EXPORT-IMPORT PROFILE
TABLE 117 PHARMACEUTICAL EXPORTS, SPAIN, 2005 AND 2006 (%)
TABLE 118 PHARMACEUTICAL IMPORTS, SPAIN, 2005 AND 2006 (%)
IMPORTANT ORGANIZATIONS IN SPAIN
NATIONAL STATISTICS INSTITUTE (INSTITUTO NACIONAL DE ESTADISTICA)
FARMAINDUSTRIA, THE NATIONAL ASSOCIATION OF THE PHARMACEUTICAL INDUSTRY IN SPAIN
AESEG, THE SPANISH ASSOCIATION OF GENERIC PHARMACEUTICALS MANUFACTURERS
ANEFP, THE NATIONALS ASSOCIATION OF OVER-THECOUNTER MEDICATIONS
CEAFA, CONFEDERACTION ESPANOLA DE FAMILIARES ENFERMOS DE ALZHEIMER’S Y OTRAS DEMENCIAS
SMALLER PHARMACEUTICAL MARKETS IN EUROPE
GREECE
INTRODUCTION
TABLE 119 OVERALL PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 120 POPULATION TRENDS, GREECE, THROUGH 2013 (MILLIONS)
FIGURE 18 GREECE: POPULATION, 1998-2013
(MILLIONS)
TABLE 121 DEMOGRAPHIC TRENDS, GREECE, THROUGH 2013 (MILLIONS)
THE GREEK HEALTHCARE SYSTEM
Structure of the Healthcare System
Healthcare Expenditures
TABLE 122 HEALTHCARE EXPENDITURE: GREECE, 2000-2005
COMMON HEALTH PROBLEMS IN GREECE
Pharmaceutical Pricing
TABLE 123 PERCENTAGE OF PRESCRIPTION PHARMACEUTICALS, BY CLASS, GREECE, 2004
REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN GREECE
FIGURE 19 VALUE BREAKDOWN OF PHARMACEUTICALS, GREECE, 2005 (%)
Growth Drivers
Barriers to Pharmaceutical Revenue Growth in Greece
MARKET SECTORS
Branded Prescription Pharmaceuticals
TABLE 124 BRANDED PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ BILLIONS)
Generic Drugs
TABLE 125 GENERIC PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ BILLIONS)
Drivers and Restraints
Over-the-Counter Medications
TABLE 126 OTC PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ MILLIONS)
TABLE 127 LEADING OTC CATEGORIES, GREECE, 2006 (% OF TOTAL MARKET)
IMPORTANT ORGANIZATIONS IN GREECE
STATISTICS GREECE
THE HELLENIC ASSOCIATION OF PHARMACEUTICAL COMPANIES (SFEE)
EFEX, THE GREEK PROPRIETARY ASSOCIATION
THE NETHERLANDS
INTRODUCTION
TABLE 128 OVERALL PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 129 POPULATION TRENDS, NETHERLANDS, THROUGH 2013 (MILLIONS)
FIGURE 20 NETHERLANDS: POPULATION, 1998-2013 (MILLIONS)
TABLE 130 DEMOGRAPHIC TRENDS, NETHERLANDS, THROUGH 2013 (MILLIONS)
THE DUTCH HEALTHCARE SYSTEM
Structure of the Healthcare System
Healthcare Expenditures
TABLE 131 HEALTHCARE EXPENDITURE: THE NETHERLANDS, 2000-2005
COMMON HEALTH PROBLEMS IN THE NETHERLANDS
Drug Pricing
REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN THE NETHERLANDS
FIGURE 21 VALUE BREAKDOWN OF PHARMACEUTICALS, NETHERLANDS, 2005 (%)
MARKET SECTORS
Branded Prescription Pharmaceuticals
TABLE 132 BRANDED PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ BILLIONS)
Generic Drugs
TABLE 133 GENERIC PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ BILLIONS)
Drivers and Restraints
Over-the-Counter Medications
TABLE 134 OTC PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ MILLIONS)
TABLE 135 LEADING OTC CATEGORIES, NETHERLANDS, 2006 (% OF TOTAL MARKET)
IMPORTANT ORGANIZATIONS IN THE NETHERLANDS
STATISTICS NETHERLANDS
NEFARMA, THE ASSOCIATION OF INNOVATE PHARMACEUTICALS IN THE NETHERLANDS
BOGIN, THE ASSOCIATION OF DUTCH GENERIC MEDICATIONS INDUSTRY
NEPROPHARM, THE NETHERLANDS ASSOCIATION OF OVER-THE-COUNTER PRODUCTS
BELGIUM
INTRODUCTION
TABLE 136 OVERALL PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 137 POPULATION TRENDS, BELGIUM, THROUGH 2013 (MILLIONS)
FIGURE 22 BELGIUM: POPULATION, 1998-2013 (MILLIONS)
TABLE 138 DEMOGRAPHIC TRENDS, BELGIUM, THROUGH 2013 (MILLIONS)
THE BELGIAN HEALTHCARE SYSTEM
Structure of the Healthcare System
TABLE 139 HEALTHCARE EXPENDITURE: BELGIUM, 2000-2005
COMMON HEALTH PROBLEMS IN BELGIUM
DRUG PRICING
REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN BELGIUM
FIGURE 23 VALUE BREAKDOWN OF PHARMACEUTICALS, BELGIUM, 2005 (%)
MARKET SECTORS
Branded Prescription Pharmaceuticals
TABLE 140 BRANDED PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ BILLIONS)
Generic Drugs
TABLE 141 GENERIC PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ BILLIONS)
Over-the-Counter Medications
TABLE 142 OTC PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ MILLIONS)
TABLE 143 LEADING OTC CATEGORIES, BELGIUM, 2006 (% OF TOTAL MARKET)
IMPORTANT ORGANIZATIONS IN BELGIUM
STATISTICS BELGIUM
PHARMA.BE, THE GENERAL ASSOCIATION OF THE MEDICINES INDUSTRY
EUROGENERICS
POLAND
INTRODUCTION
TABLE 144 OVERALL PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 145 POPULATION TRENDS, POLAND, THROUGH 2013 (MILLIONS)
FIGURE 24 POLAND: POPULATION, 1998-2013 (MILLIONS)
TABLE 146 DEMOGRAPHIC TRENDS, POLAND, THROUGH 2013 (MILLIONS)
COMMON HEALTH PROBLEMS IN POLAND
THE POLISH HEALTHCARE SYSTEM
Structure of the Healthcare System
TABLE 147 HEALTHCARE EXPENDITURE: POLAND, 2000-2005
DRUG PRICING
MARKET SECTORS
Branded Prescription Pharmaceuticals
TABLE 148 BRANDED PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ BILLIONS)
Generic Drugs
TABLE 149 GENERIC PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ BILLIONS)
Over-the-Counter Medications
TABLE 150 OTC PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ MILLIONS)
TABLE 151 LEADING OTC CATEGORIES, POLAND, 2006 (% OF TOTAL MARKET)
IMPORTANT ORGANIZATIONS IN POLAND
POLISH CENTRAL STATISTICS OFFICE
POLFARMED, POLISH CHAMBER OF PHARMACEUTICALS INDUSTRY AND MEDICAL DEVICES
PASMI, THE POLISH ASSOCIATION OF THE SELFMEDICATION INDUSTRY
PORTUGAL
INTRODUCTION
TABLE 152 OVERALL PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 153 POPULATION TRENDS, PORTUGAL, THROUGH 2013 (MILLIONS)
FIGURE 25 PORTUGAL: POPULATION, 1998-2013 (MILLIONS)
TABLE 154 DEMOGRAPHIC TRENDS, PORTUGAL, THROUGH 2013 (MILLIONS)
THE PORTUGUESE HEALTHCARE SYSTEM
Structure of the Healthcare System
TABLE 155 HEALTHCARE EXPENDITURE: PORTUGAL, 2000-2005
Pharmaceutical Pricing
FIGURE 26 VALUE BREAKDOWN OF PHARMACEUTICALS, PORTUGAL, 2005 (%)
FIGURE 26 (CONTINUED)
COMMON HEALTH PROBLEMS IN PORTUGAL
MARKET SECTORS
Branded Prescription Pharmaceuticals
TABLE 156 BRANDED PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ BILLIONS)
Generic Drugs
TABLE 157 GENERIC PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ BILLIONS)
Over-the-Counter Medications
TABLE 158 OTC PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ MILLIONS)
TABLE 159 LEADING OTC CATEGORIES, PORTUGAL, 2006 (% OF TOTAL MARKET)
IMPORTANT ORGANIZATIONS IN PORTUGAL
STATISTICS PORTUGAL
APOGEN, PORTUGUESE ASSOCIATION OF GENERIC MEDICATIONS
APIFARMA, THE ASSOCIATION OF THE PORTUGUESE PHARMACEUTICAL INDUSTRY
SWITZERLAND
INTRODUCTION
TABLE 160 OVERALL PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 161 POPULATION TRENDS, SWITZERLAND, THROUGH 2013 (MILLIONS)
FIGURE 27 SWITZERLAND: POPULATION, 1998-2013 (MILLIONS)
TABLE 162 DEMOGRAPHIC TRENDS, SWITZERLAND, THROUGH 2013 (MILLIONS)
Common Health Problems in Switzerland
THE SWISS HEALTHCARE SYSTEM
Structure of the Healthcare System
TABLE 163 HEALTHCARE EXPENDITURE: SWITZERLAND, 2000-2005
Pharmaceutical Environment and Pricing
Pharmaceutical Environment ?(Continued)
FIGURE 28 VALUE BREAKDOWN OF PHARMACEUTICALS, SWITZERLAND, 2005 (%)
MARKET SECTORS
Branded Prescription Pharmaceuticals
TABLE 164 BRANDED PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ BILLIONS)
Generic Drugs
TABLE 165 GENERIC PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ BILLIONS)
Over-the-Counter Medications
TABLE 166 OTC PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ MILLIONS)
TABLE 167 LEADING OTC CATEGORIES, SWITZERLAND, 2006 (% OF TOTAL MARKET)
IMPORTANT ORGANIZATIONS IN SWITZERLAND
SWISS FEDERAL STATISTICS OFFICE
COMPANY PROFILES
NOVARTIS INTERNATIONAL AG
SWEDEN
INTRODUCTION
TABLE 168 OVERALL PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 169 POPULATION TRENDS, SWEDEN, THROUGH 2013 (MILLIONS)
FIGURE 29 SWEDEN: POPULATION, 1998-2013 (MILLIONS)
TABLE 170 DEMOGRAPHIC TRENDS, SWEDEN, THROUGH 2013 (MILLIONS)
HEALTH PROBLEMS AND HEALTHCARE IN SWEDEN
The Healthcare System
TABLE 171 HEALTHCARE EXPENDITURE: SWEDEN, 2000-2005
Pharmaceutical Pricing
FIGURE 30 VALUE BREAKDOWN OF PHARMACEUTICALS, SWEDEN, 2005 (%)
Health Problems in Sweden
TABLE 172 LEADING THERAPEUTIC CATEGORIES, SWEDEN, 2006 (% OF TOTAL MARKET, BY VALUE)
MARKET SECTORS
Branded Pharmaceuticals
TABLE 173 BRANDED PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ BILLIONS)
Generic Drugs
TABLE 174 GENERIC PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ BILLIONS)
Over-the-Counter Medications
TABLE 175 OTC PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ MILLIONS)
IMPORTANT ORGANIZATIONS IN SWEDEN
STATISTICS SWEDEN
FGL, THE SWEDISH ASSOCIATION FOR GENERIC PHARMACEUTICALS
AUSTRIA
INTRODUCTION
TABLE 176 OVERALL PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 177 POPULATION TRENDS, AUSTRIA, THROUGH 2013 (MILLIONS)
FIGURE 31 AUSTRIA: POPULATION, 1998-2013 (MILLIONS)
TABLE 178 DEMOGRAPHIC TRENDS, AUSTRIA, THROUGH 2013 (MILLIONS)
HEALTHCARE AND HEALTH PROBLEMS IN AUSTRIA
The Healthcare System
Pharmaceutical Pricing
TABLE 179 HEALTHCARE EXPENDITURE: AUSTRIA, 2000-2005
Health Problems in Austria
MARKET SECTORS
Branded Prescription Pharmaceuticals
TABLE 180 BRANDED PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ BILLIONS)
Generic Drugs
TABLE 181 GENERIC PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ BILLIONS)
Over-the-Counter Medications
TABLE 182 OTC PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ MILLIONS)
IMPORTANT ORGANIZATIONS IN AUSTRIA
STATISTICS AUSTRIA
PHARMIG, THE
IGEPHA, THE AUSTRIAN SELF-MEDICATION INDUSTRY
HUNGARY
INTRODUCTION
TABLE 183 OVERALL PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
HEALTH PROBLEMS AND HEALTHCARE IN HUNGARY
The Healthcare System
Pharmaceutical Pricing
Health Problems in Hungary
MARKET SECTORS
Branded Prescription Pharmaceuticals
TABLE 184 BRANDED PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ BILLIONS)
Generic Drugs
TABLE 185 GENERIC PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ BILLIONS)
Over-the-Counter Medications
TABLE 186 OTC PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ MILLIONS)
IMPORTANT ORGANIZATIONS IN HUNGARY
HUNGARIAN CENTRAL STATISTICS OFFICE
MAGYOSZ, THE HUNGARIAN PHARMACEUTICAL MANUFACTURERS ASSOCIATION
FINLAND
INTRODUCTION
TABLE 187 OVERALL PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ BILLIONS)
POPULATION AND DEMOGRAPHICS
TABLE 188 POPULATION TRENDS, FINLAND, THROUGH 2013 (MILLIONS)
TABLE 189 DEMOGRAPHIC TRENDS, FINLAND, THROUGH 2013 (MILLIONS)
HEALTH PROBLEMS AND HEALTHCARE IN FINLAND
The Healthcare System
PHARMACEUTICAL PRICING
Health Problems in Finland
MARKET SECTORS
TABLE 190 LEADING THERAPEUTIC CATEGORIES, FINLAND, 2006 (% OF TOTAL MARKET, BY VALUE)
Branded Prescription Pharmaceuticals
TABLE 191 BRANDED PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ BILLIONS)
Generic Drugs
For full details, please email keithw@cmsinfo.com
Top of Page
Buy now!
Top of Page
|
|
